CeriBell (NASDAQ:CBLL) Major Shareholder Tpg Gp A, Llc Sells 202,368 Shares

CeriBell, Inc. (NASDAQ:CBLL) major shareholder Tpg Gp A, Llc sold 202,368 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $20.12, for a total transaction of $4,071,644.16. Following the transaction, the insider directly owned 3,765,054 shares of the company’s stock, valued at $75,752,886.48. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

CeriBell Stock Down 2.6%

CBLL stock opened at $19.45 on Wednesday. The company has a market capitalization of $737.93 million, a P/E ratio of -11.93 and a beta of 0.84. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $24.33. The firm’s fifty day simple moving average is $18.86 and its 200-day simple moving average is $19.73. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The business had revenue of $26.49 million during the quarter, compared to analysts’ expectations of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. As a group, equities research analysts forecast that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CBLL shares. Canaccord Genuity Group decreased their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.20.

Institutional Trading of CeriBell

A number of institutional investors and hedge funds have recently made changes to their positions in CBLL. Russell Investments Group Ltd. raised its stake in shares of CeriBell by 41.4% during the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after buying an additional 854 shares during the period. Sei Investments Co. raised its position in CeriBell by 2.3% during the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after acquiring an additional 1,125 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares in the last quarter. Deutsche Bank AG grew its position in shares of CeriBell by 1.7% in the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares during the period. Finally, Strs Ohio purchased a new stake in shares of CeriBell during the first quarter worth about $27,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.